Single-Cell Analysis Stocks

Precision life sciences firms in this sector develop high-resolution instrumentation and reagents to profile biological processes at the individual cell or molecule level, moving beyond the limitations of bulk genomic sequencing.

As of Oct 23, 2026, Single-Cell Analysis has 3 US-listed companies worth $10.5B combined. The median member moved +2.4% over the past week; NAUT led at +57.3% and LAB trailed at -3.7%.